Hormonal
High-intensity intensive training (approx. 90% VO2peak) for 8 weeks increases parasympathetic autonomic activity and aerobic performance (VO2peak), whereas subsequent overload training (5/3x workload) shifts autonomic balance toward sympathetic dominance, indicating fatigue.
To improve aerobic fitness, you need to train hard (around 90% of your max capacity). This will initially increase your body's restorative (parasympathetic) activity. If you push too hard without rest (overload), your stress (sympathetic) system takes over, signaling fatigue. Use heart rate variability to monitor this shift: a drop in parasympathetic markers suggests you need recovery to avoid overtraining.
Globally, there was a progressive increase of both the parasympathetic and sympathetic indices with a shift of the autonomic nervous system equilibrium toward a predominance of the parasympathetic arm simultaneously to an increase of the aerobic performance during the 2-month intensive training period... During the overload training period... there was a stagnation of the parasympathetic indices associated to a progressive increase in sympathetic activity (LF/HF, P < 0.05).
Why this rating
Controlled laboratory study with repeated measures and statistical significance, but small sample size (n=6).
Source
Autonomic adaptations to intensive and overload training periods: a laboratory study
Vincent Pichot et al. · Medicine & Science in Sports & Exercise · 2002
DOI 10.1097/00005768-200210000-00019
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →